Kantar Media May 2022 Med/Surg Readership Study (Onc)
Journal of Clinical Oncology (JCO) serves its readers as the most credible and authoritative resource for disseminating significant clinical oncology research. In print and online, JCO strives to publish the highest quality articles dedicated to clinical research.
Original Reports are the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other articles that relate to the care of patients with cancer.
Acceptance of articles to online publication time: 41 days
Acceptance of articles to print publication time: 104 days
Manuscript acceptance rate: 20% (12% for Original Reports)
Clarivate, 2021 Journal Citation Reports, June 2022
Journal Citation Reports, June 2022
U.S. Primary Focus of Professional Activity |
|
---|---|
Breast Cancer |
4,224 |
Clinical Trials/Biostatistics/Epidemiology |
3,585 |
Lung Cancer |
3,048 |
Gastrointestinal Cancer |
2,451 |
Drug Development |
2,302 |
Genitourinary Cancer |
3,232 |
Tumor Biology |
968 |
Gynecologic Cancer |
1,207 |
Liver Cancer |
987 |
Developmental Therapeutics |
1,329 |
Biologic Therapy |
1,156 |
Head and Neck Cancer |
1,117 |
Cancer Education |
1,485 |
BMT (Autologous/Allogeneic/Stem Cell) |
827 |
Note: Members may choose more than one category and not all give a response. Updated May 2022.
U.S. Board Certification |
|
---|---|
Medical Oncology |
9,487 |
Internal Medicine |
8,910 |
Hematology |
5,995 |
Radiation Oncology |
1,128 |
Surgery (incl. Surgical Oncology) |
679 |
Other |
3,407 |
Pediatrics (incl. Pediatric Oncology) |
1,038 |
Gynecologic Oncology |
392 |
Oncology Pharmacy |
323 |
Oncology Nurse |
254 |
U.S. Practice Location |
|
---|---|
Academic Medical Center/University |
11,540 |
Private Practice (Office or Hospital Based) |
6,601 |
Training Program |
4,100 |
Pharmaceutical/Biotech Company |
6,164 |
Administration |
749 |
Government Agency |
426 |
Staff Model HMO |
264 |
Laboratory Research |
326 |
Staff Model HMO |
264 |
Specialty |
Circulation |
---|---|
Medical Oncology |
2,723 |
Hematology/Oncology |
5,180 |
Radiation Oncology |
597 |
Internal Medicine |
990 |
Surgical Oncology |
400 |
Gynecologic Oncology |
270 |
Pediatric Hematology-Oncology |
151 |
Urology |
100 |
Pathology |
63 |
Oncology Pharmacy |
57 |
Neurology |
85 |
Hospice and Palliative Medicine |
112 |
ASCO Members-in-training |
2,584 |
Other* |
2,750 |
TOTAL |
16,062 |
*Includes Oncology Nurse, Physician Assistant, Dermatology, Gastroenterology, and other field-related personnel.
Issue |
Insertion |
Ad |
Insert Material |
Bonus Distribution |
---|---|---|---|---|
Jan 1st |
11/23/22 |
11/30/22 |
12/7/22 |
|
Jan 10th |
12/7/22 |
12/14/22 |
12/21/22 |
ASCO GI - ASCO Gastrointenstinal |
Jan 20th |
12/16/22 |
12/23/22 |
12/30/22 |
|
Feb 1st |
12/28/22 |
1/4/23 |
1/11/23 |
ASCO GU - ASCO Genitourinary |
Feb 10th |
1/6/23 |
1/13/23 |
1/20/23 |
|
Feb 20th |
1/18/23 |
1/25/23 |
2/1/23 |
|
Mar 1st |
1/25/23 |
2/1/23 |
2/8/23 |
|
Mar 10th |
2/3/23 |
2/10/23 |
2/17/23 |
HOPA - Hematology/Oncology Pharmacy Association |
Mar 20th |
2/15/23 |
2/22/23 |
3/1/23 |
NCCN Annual Conference, American Physiology Summit (formerly Experimental Biology) |
Apr 1st |
2/27/23 |
3/6/23 |
3/13/23 |
|
Apr 10th |
3/8/23 |
3/15/23 |
3/22/23 |
ONS - Oncology Nursing Society & American College of Physicians (ACP) |
Apr 20th |
3/17/23 |
3/24/23 |
3/31/23 |
|
May 1st |
3/29/23 |
4/5/23 |
4/12/23 |
|
May 10th |
4/6/23 |
4/13/23 |
4/20/23 |
|
May 20th |
4/14/23 |
4/21/23 |
4/28/23 |
ASCO Annual Meeting |
Jun 1st |
4/27/23 |
5/4/23 |
5/11/23 |
ASCO Annual Meeting |
Jun 10th |
5/5/23 |
5/12/23 |
5/19/23 |
|
Jun 20th |
5/16/23 |
5/23/23 |
5/30/23 |
|
Jul 1st |
5/26/23 |
6/2/23 |
6/9/23 |
|
Jul 10th |
6/5/23 |
6/12/23 |
6/19/23 |
Best of ASCO Seattle & ASCO Breakthrough |
Jul 20th |
6/15/23 |
6/22/23 |
6/29/23 |
|
Aug 1st |
6/26/23 |
7/3/23 |
7/10/23 |
|
Aug 10th |
7/7/23 |
7/14/23 |
7/21/23 |
|
Aug 20th |
7/14/23 |
7/21/23 |
7/28/23 |
IASLC World Lung Conference |
Sep 1st |
7/27/23 |
8/3/23 |
8/10/23 |
|
Sep 10th |
8/4/23 |
8/11/23 |
8/18/23 |
NCCN Heme |
Sep 20th |
8/16/23 |
8/23/23 |
8/30/23 |
ASTRO - American Society for Radiation Oncology, ESMO - European Society for Medical Oncology |
Oct 1st |
8/25/23 |
9/1/23 |
9/8/23 |
|
Oct 10th |
9/6/23 |
9/13/23 |
9/20/23 |
ASCO Quality Care & American Society of Human Genetics (ASHG) |
Oct 20th |
9/15/23 |
9/22/23 |
9/29/23 |
JADPRO Live |
Nov 1st |
9/27/23 |
10/4/23 |
10/11/23 |
|
Nov 10th |
10/6/23 |
10/13/23 |
10/20/23 |
|
Nov 20th |
10/16/23 |
10/23/23 |
10/30/23 |
ASH - American Society of Hematology & SABCS - San Antonio Breast Cancer Symposium |
Dec 1st |
10/26/23 |
11/2/23 |
11/9/23 |
|
Dec 10th |
11/2/23 |
11/9/23 |
11/16/23 |
|
Dec 20th |
11/15/23 |
11/22/23 |
11/29/23 |
Please send all insertion orders to hspadorders@hbside.com
Frequency |
Full Page |
1/2 Page |
1/4 Page |
---|---|---|---|
1x |
$4,070 |
$2,630 |
$1,520 |
6x |
$3,950 |
$2,430 |
$1,440 |
12x |
$3,875 |
$2,385 |
$1,410 |
24x |
$3,740 |
$2,340 |
$1,375 |
36x |
$3,620 |
$2,295 |
$1,345 |
48x |
$3,555 |
$2,225 |
$1,315 |
60x |
$3,550 |
$2,215 |
$1,315 |
72x |
$3,535 |
$2,205 |
$1,315 |
96x |
$3,445 |
$2,115 |
$1,315 |
120x |
$3,410 |
$2,075 |
$1,315 |
144x |
$3,375 |
$2,060 |
$1,315 |
170x |
$3,280 |
$2,015 |
$1,315 |
194x |
$3,235 |
$2,015 |
$1,315 |
216x |
$3,225 |
$2,015 |
$1,315 |
242x |
$3,175 |
$2,015 |
$1,315 |
268x |
$3,155 |
$2,015 |
$1,315 |
304x |
$3,105 |
$2,015 |
$1,315 |
340x |
$3,045 |
$2,015 |
$1,315 |
376x |
$3,020 |
$2,015 |
$1,315 |
Frequency |
2-Page |
4-Page |
6-Page |
8-Page |
---|---|---|---|---|
1x |
$9,340 |
$17,480 |
$25,620 |
$33,760 |
6x |
$9,100 |
$17,000 |
$24,900 |
$32,800 |
12x |
$8,950 |
$16,700 |
$24,450 |
$32,200 |
24x |
$8,680 |
$16,160 |
$23,640 |
$31,120 |
36x |
$8,440 |
$15,680 |
$22,920 |
$30,160 |
48x |
$8,310 |
$15,420 |
$22,530 |
$29,640 |
60x |
$8,300 |
$15,400 |
$22,500 |
$29,600 |
72x |
$8,270 |
$15,340 |
$22,410 |
$29,480 |
96x |
$8,090 |
$14,980 |
$21,870 |
$28,760 |
120x |
$8,020 |
$14,840 |
$21,660 |
$28,480 |
144x |
$7,950 |
$14,700 |
$21,450 |
$28,200 |
170x |
$7,760 |
$14,320 |
$20,880 |
$27,440 |
194x |
$7,670 |
$14,140 |
$20,610 |
$27,080 |
216x |
$7,650 |
$14,100 |
$20,550 |
$27,000 |
242x |
$7,550 |
$13,900 |
$20,250 |
$26,600 |
268x |
$7,510 |
$13,820 |
$20,130 |
$26,440 |
304x |
$7,410 |
$13,620 |
$19,830 |
$26,040 |
340x |
$7,290 |
$13,380 |
$19,470 |
$25,560 |
376x |
$7,240 |
$13,280 |
$19,320 |
$25,360 |
Color Charges |
|
---|---|
4 color |
$2,640 |
2 color standard |
$970 |
2 color matched |
$1,050 |
5 color |
$3,610 |
Other color charges |
Contact Harborside at |
Rates (Supplied) |
|
---|---|
U.S. Only |
$23,350 Net/Issue |
Price based on 2-4 page outsert within specs
Frequency |
2-PG Supplied |
2-PG PLUS PI |
---|---|---|
1x |
$28,020 |
$34,020 |
6x |
$27,300 |
$33,300 |
12x |
$26,850 |
$32,850 |
24x |
$26,040 |
$32,040 |
36x |
$25,320 |
$31,320 |
48x |
$24,930 |
$30,930 |
60x |
$24,900 |
$30,900 |
72x |
$24,810 |
$30,810 |
96x |
$24,270 |
$30,270 |
120x |
$24,060 |
$30,060 |
144x |
$23,850 |
$29,850 |
170x |
$23,280 |
$29,280 |
194x |
$23,010 |
$29,010 |
216x |
$22,950 |
$28,950 |
242x |
$22,650 |
$28,650 |
268x |
$22,530 |
$28,530 |
304x |
$22,230 |
$28,230 |
340x |
$21,870 |
$27,870 |
376x |
$21,720 |
$27,720 |
Prices are net and for supplied materials.
Rates | |
---|---|
U.S. Only | $17,480 net (2-page) |
Rates include printing.
Rates are for 2-page ad units plus the removable tab.
For larger ad units, please contact Harborside for a custom quote.
To reach the full circulation, including ex-U.S. distribution, add 25% to domestic gross rates above.
Please contact Harborside directly for any non-U.S. circulation inquiries.
Maximize your exposure with the #1 Read Oncology Publications! Run your advertisement in all 6 issues of the ASCO Publications Network in the same month
Monthly Package Includes:
If multiple sized ad units are placed within the first 5 insertions, the cost of the 6th ad unit will be determined by the average dollar amount spent per issue. This amount will be credited toward the 6th insertion in a series.
Advertisers in ASCO Publications: Journal of Clinical Oncology (JCO), The ASCO Post, and JCO Oncology Practice combine for pages to earn the frequency rate in JCO as well as in all the ASCO publications. Space purchased by a parent company and subsidiaries is combined in calculating the earned rate. When the number of insertions is greater or less than indicated by the contract, rates are adjusted accordingly. Please contact Harborside for details. Frequency will be determined by the total number of pages placed in these publications during a calendar year.
*Guaranteed frequency is based on the number of pages placed between July 2021-June 2022
Advertise three or more prescribing information (PI) pages for a single ad for a brand and receive a 50% discount on the B&W page rate beginning on the third PI page. Multi-journal discount is not eligible on discounted PI pages.
hspadmats@hbside.com
FTP: prodweb2.hbrsd.com
Username: hspsales
Password: Connect#9
Norman W. Virtue
Tel: 631-935-7682
Fax: 631-692-0805
Norman Virtue
244 Hillside Ave
Valley Stream, NY 11580
Quad
JCO - JCO004/Issue Date
Attn: Stacy Darby
555 South 108th Street
West Allis, WI 53214-1145
414-566-3500
Quad
ONP - ONP004/Issue Date
Stacy Darby
4766 N Dickenson Rd
Coleman, MI 48618
JCO - JCO004/Issue Date
Norman Virtue
244 Hillside Ave
Valley Stream, NY 11580
SWOP standards apply. Submit only high-resolution CMYK PDF formatted files. Convert all spot colors to CMYK. All fonts and images must be embedded. Files should indicate trim and bleed.
Contact the Production Manager at nvirtue@hbside.com for additional specifications and production questions.
Ad Sizes |
Bleed |
Trim |
Live |
---|---|---|---|
2-Page spread |
16.5″ × 11.125″ |
16.25″ × 10.875″ |
15.75″ × 10.375″* |
Full Page |
8.375″ × 11.125″ |
8.125″ × 10.875″ |
7.625″ × 10.375″ |
1/2-Page (vertical) |
4.25″ × 11.125″ |
3.875″ × 10.875″ |
3.5″ × 10.375″ |
1/2-Page (horizontal) |
8.375″ × 5.625″ |
8.125″ × 5.25″ |
7.625″ × 4.75″ |
1/4-Page (square) |
4.25″ × 5.625″ |
3.875″ × 5.25″ |
3.5″ × 4.75″ |
*with a 0.5″ safety down the middle
Insert Requirements |
|
---|---|
2-Page Insert |
8-3/8″ × 11-1/8″ |
4-Page Insert |
16.75" × 11.125", supply folded 8.375" × 11.125" |
Trimming |
0.125" top, bottom, gutter, and outside edge; margin for live matter 0.5" inside all edges of untrimmed insert |
Stock |
80#–100# text stock maximum |
Quantity |
U.S. Only: 18,500 per run, |
All inserts must be supplied as a single unit
Outserts are a premium position offered in each issue. Availability is limited. Please contact Harborside for information regarding outsert list matching, printing, and availability.
Dimensions: Outsert dimensions are limited by the host publication (8.125″ x 10.875″). Outserts should be no smaller than 4″ x 6″.
Artwork, design, and content must be approved prior to printing.
Outsert may be no heavier than 3 oz.
Contact: Norman W. Virtue (nvirtue@hbside.com)
Harborside will print upon request. Printing fee is $2,500 net for a standard 2-page cover-tip. For larger units, please contact us for custom quote.
Cover Tips are available on all issues.
Dimensions: 3-1/2″ × 6″
Single leaf and single fold only, indicate front on order.
Multiple page cover tips require wafer seals on all open edges; those inclusive of PI could have an upcharge. Artwork, design, and content must be approved prior to printing.
70 lb. minimum text stock required.
Harborside will print upon request. Printing fee is $2,500 net for a standard 2-page cover-tip. For larger units, please contact us for custom quote.
Journal Marks offer advertisers excellent visibility by providing JCO readers a removable tab that carries your message.
Journal Marks may run within the editorial well.
Artwork, design, and content must be approved by ASCO.
The folded dimensions are 9.875" × 11.125".
For a detailed diagram view the following PDF:
Journal Mark SpecsContact: Norman W. Virtue (nvirtue@hbside.com)
Harborside will match any client list to JCO's circulation. The first 2 list matches are free, and a charge of $2,000 applies to all subsequent matches. If the client chooses to advertise to the selected audience through a demo insert, the appropriate demo charge will apply, and the initial list match fee will be waived. Maximum of 2 list matches per year per brand.
The Best of JCO–Top ASCO Abstracts editions are a compilation of ASCO's Top Abstracts presented at the ASCO Annual Meeting. These editions are tumor-specific.
Digital | Website | ||||
---|---|---|---|---|---|
Abstract Edition | Mail Date | Print Circulation | eTOC #1 | eTOC #2 | Impressions |
Breast | 6/10 | 2,260 | 18,000 | 2,500 | 200–800 |
Multiple Myeloma | 7/1 | 5,100 | 18,000 | 4,250 | 200–800 |
Gastrointestinal | 6/10 | 2,400 | 18,000 | 1,800 | 200–800 |
Genitourinary | 6/20 | 1,600 | 18,000 | 1,400 | 200–800 |
Gynecologic | 7/1 | 2,500 | 18,000 | 700 | 200–800 |
Hematologic Malignancies | 6/20 | 5,100 | 18,000 | 4,000 | 200–800 |
Lung | 6/10 | 1,800 | 18,000 | 1,500 | 200–800 |
Immunotherapy | 6/20 | 16,000 | 18,000 | 1,900 | 200–800 |
Other* | 6/10 | TBD | 18,000 | 200-800 |
*CNS, Head and Neck, Melanoma/Skin Cancer, Sarcoma, Supportive Care, etc. Please contact your representative for details.
The Best of JCO–Conference editions are a compilation of JCO's top-accessed content relevant to the subject matter of the meeting it is distributed at.
Digital | Website | |||
---|---|---|---|---|
Conference | Mail Date | eTOC #1 | eTOC #2 | Impressions |
Gastrointestinal Cancers Symposium | 1/20 | 18,000 | 1,400 | 200–800 |
Genitourinary Cancers Symposium | 2/10 | 18,000 | 1,400 | 200–800 |
Best of JCO Thoracic Cancer Edition (IASLC) | 10/10 | 18,000 | 1,500 | 200–800 |
Best of JCO Medical Oncology Edition (ESMO) | 10/20 | 18,000 | 5,000 | 200–800 |
Best of JCO Radiation Oncology (ASTRO) | 10/1 | 18,000 | 600 | 200–800 |
Best of JCO Breast Cancer Edition (SABCS) | 12/10 | 18,000 | 2,500 | 200–800 |
*Conference Distribution subject to change
SOV #1 | SOV #2 | |
---|---|---|
|
Cover Tip + TOC | Cover 2 + Cover 4 |
eTOCs |
Email #1 + Email #2 (Leaderboard) |
Email #1 + Email #2 (Medium Rectangle) |
Website |
50% of impressions | 50% of impressions |
Cost |
$60,000 net | $60,000 net |
Maximum trim size: 8" wide × 5.5" high
Minimum trim size: 4" wide × 4" high
*larger cover tips accepted
The JCO eTOC features links and abstracts to articles posted online, before the print issue is released. Sponsorship includes 33% share of voice (SOV) on one eTOC.
Default is U.S. only for advertisers. International targeted coverage is available, inquire for pricing.
Discounts available for 6, 12 and 24 sends.
Please contact your representative for details.
The JCO Featured Articles E-Alerts are a compilation of JCO's most recent top-downloaded original reports related to your target audience. All programs will be sent to ASCO member self-identified specialists.
Cost per send: $8,000
Frequency: 3× per year
Share of Voice (SOV): 100%
Circulation: Varies by Specialty (see chart below)
Open rate: 40%
TOPIC* | Distribution |
---|---|
Breast |
2,500 |
Multiple Myeloma |
4,250 |
Gastrointestinal |
1,800 |
Genitourinary |
1,400 |
Gynecologic |
700 |
Hematologic Malignancies |
4,000 |
Lung |
1,500 |
Immunotherapy |
1,900 |
*Other topics may be available, contact your sales representative.
The Top Downloaded Articles E-Alerts feature the top downloaded articles from both the JCO and JCO -OP websites.
January, April, July, October*
17,000
50%
40%
The Editor's Pick E-Alert features JCO's top articles, chosen by the editors at ASCO.
March, June, September, December*
17,000
50%
37%
ASCO Publication's Annual Meeting E-Alert features two emails in conjunction with the ASCO Annual meeting; one is sent pre-conference, and the second is sent during the conference.
May & June*
19,500+
100%
36%
*Send month subject to change
Source: Medical/Surgical-Media Measurement, 2022. Source Table 101
*based on US average stats October 2022, Google Analytics, Google DFP, Google Ad Manager, Kantar Website Usage Study 2022
For more information on international metrics/pricing, please contact your representative.
ETarget List Segments include banner impressions on the ASCO Publications Network (Web & Email) to the your NPI matched List. This segment also includes contextual and behavioral target impressions
NEW: HCP Level Data is now available!
Reporting will be provided weekly or monthly (depending upon campaign) based on appending user behavioral data to advertiser provided lists (PII).
25% SOV
25% SOV
*Check on conference timing availability and pricing
Specification | Website | eTOC |
---|---|---|
Accepted ad sizes |
Leaderboard (728 × 90) Medium Rectangle (300 × 250) Mobile (320/300 x 50) |
Leaderboard (728 × 90) Medium Rectangle (300 × 250) |
Ad expansion sizes |
Leaderboard (728 × 315) (Expands down) Medium Rectangle (600 × 250) (Expands left) |
N/A |
Ad expansion notes |
Ad must require user click initiation for expansion. Expanded ad must include clearly visible close controls. Rollover to expand ads are not accepted. |
N/A |
Ad formats |
JPG, GIF, HTML5, Javascript,third-party served ads |
JPG, GIF, animated GIF |
Maximum initial file size |
160K |
60K |
Rich media file size |
200K |
N/A |
Animation time |
15 seconds, 3 frames, 3 loops |
15 seconds, 3 frames, 3 loops |
Frames per second (FPS) |
24 FPS |
24 FPS |
Border |
All ads with white or partially white background must use a 1-pixel dark color border |
All ads with white or partially white background must use a 1-pixel dark color border |
Maximum Ad Resource Requests*** |
15 |
N/A |
All ad creative is due one week prior to live date and is subject to approval by ASCO. Email creative must be finalized no later than 72 hours prior to deployment. HTML5 ads must be provided as soon as possible for testing purposes.
All ad creative is subject to approval from the American Society of Clinical Oncology. For times when the user's browser does not support creative functionality (i.e. Flash™, HTML5), provide a standard image file.
Animated .gif files should resolve into a comprehensive static image.
***Resource request limits include any tracking scripts that the agency/advertiser may be utilizing in conjunction with their campaign.
Interactive ads will allow for unlimited file load after user-initiated interaction. User initiation is the willful act of a user to engage with an ad. Users may interact by clicking on the ad.
File weight calculation: All files for the ad, including supporting files and agency supplied tracking scripts, must be included as part of the maximum file weight calculation for all file limits load.
Keyword Blocking: If a keyword blocker is being utilized, all keywords need to be included within the IO in advance of acceptance. Failure to do so, will result in advertiser being billed for blocked impressions.
HTML5 Best Practice Notes:
Ads must not load more than 15 supporting files, including any agency supplied tracking scripts.
Use well-distributed, cached libraries to provide supporting files instead of providing them with the ad.
Check device and bandwidth and tailor supporting files and other elements to the environment and experience.
Harborside utilizes a number of viewability/IVT analyzation tools for comprehensive data on advertising Campaigns. If there is a 10% difference between third-party reporting, a conversation ensues between client and Harborside.
No Advertising shall include any pixels, tags, Flash containers, or any other type of information collection software code (i.e. any such pixel, tag, code or device commonly referred to as a "Pixel"), nor place any beacons, cookies, or other information collection devices on the browsers of users unless expressly approved in writing by Harborside. If Harborside approves the inclusion of a Pixel in an advertisement, then unless and only to the extent that such approval contains an express exception, (i) Advertiser may not use such Pixel to collect any personally-identifiable information (PII) with respect to any JCO user, (ii) no such Pixel can be flash or object based, (iii) No cookies may be placed on a user's system, (iv) Advertiser will not link any non-PII that it collects to any PII that it may have from any other source and (v) Advertiser will not update any existing profile or create any profile in its database based on any data collected on the JCO site, including the fact that someone is a JCO user or any information derived from the information in the referring URL.
We cannot honor viewability related campaign goals if ads are supplied that do not meet the specifications supplied in the grid above.
IVT-related campaign requirements cannot be honored if logs including IP addresses and timestamps are not supplied of suspected IVT-generated impressions for verification. These logs also enable us to ensure that we filter out future IVT visitations from these addresses if deemed valid. Harborside will supply a report back of any IVT traffic deemed valid along with supporting evidence.
All advertising is subject to approval of the Editor-in-Chief, publisher and advertising representative, and ASCO. New advertisements are to be received by the publisher and advertising representative at least two weeks before the closing date. Please email all ad proofs to Norman W. Virtue at nvirtue@hbside.com. The publisher and advertising representative reserves the right to label any advertisement as such for any ads that contain significant editorial content or that look like editorial pages.
The advertiser and advertising agency accept and assume liability for all content (including text, representations, illustrations, opinions, and facts) of advertisements and their compliance with all applicable laws and regulations and also assume responsibility for any claims made against the publisher and advertising representative or ASCO arising from or related to such advertisements.
Advertiser and advertising agency recognize and accept that the following language appears within the publication:
"The ideas and opinions expressed in JCO do not necessarily reflect those of ASCO. The mention of any product, service, or therapy in this publication or in any advertisement in this publication should not be construed as an endorsement of the products mentioned."
In the event that legal action or a claim is made against the publisher and advertising representative or ASCO arising from or related to such advertisements, the advertiser and advertising agency agree to fully defend, indemnify, and hold harmless the publisher and advertising representative and ASCO and to pay any judgment, expenses, and legal fees incurred by the publisher and advertising representative or ASCO as a result of said legal action or claim.
In addition, the publisher and advertising representative reserves the right to reject or discontinue any advertising for any reason. This right shall not be deemed to have been waived by acceptance or actual use of any advertising matter.
The publisher and advertising representative reserves the right to label any advertisement as such for any ads that contain significant editorial content or that look like text pages. The publisher and advertising representative is not liable for delays in delivery and/or nondelivery due to any condition beyond the control of the publisher and advertising representative affecting production or delivery in any manner.
The publisher and advertising representative reserves the right to reject any advertising that it believes is not in keeping with the publication's standards.
Advertiser and advertising agency agree to indemnify, defend, and hold harmless the publisher and advertising representative from any and all liability for content (including text, illustrations, representatives, sketches, maps, trademarks, labels, or other copyrighted matter) of advertisement printed or the unauthorized use of any person's name or photography arising from the publisher's reproduction and publishing of such advertisements pursuant to the advertiser's or agency's order.
The publisher and advertising representative is not liable for delays in delivery and/or nondelivery in the event of an Act of God, action by any governmental or quasi-governmental entity, fire, flood, insurrection, riot, explosion, embargo, strikes (whether legal or illegal), labor or material shortage, transportation interruption of any kind, work slow-down, or any condition beyond the control of the publisher and advertising representative affecting production or delivery in any manner.
Insertion Order and Copy Regulations: Insertion instructions shall be supplied for every advertisement and shall clearly state the following information: name of publication, name of advertiser, date to be inserted, size of advertisement, identification of advertisement (proof of ad to be furnished if possible), plus any special instruction such as bleed and color.
Cancellation of space order forfeits the right to position protection.
The publisher and advertising representative's liability for any error will not exceed the charge for the advertisement in question.
The publisher and advertising representative assumes no liability if for any reason it becomes necessary to omit an advertisement.
When change of copy, covered by an uncancelled insertion order, is not received by the closing date, copy run in the previous issue will be inserted.
Requests for specified position at ROB rates are given consideration, but no guarantee is made unless the position premium has been agreed to in the contract.
The publisher and advertising representative reserves the right to hold advertiser and/or its advertising agency jointly and severally liable for such monies as are due and payable to the publisher and advertising representative.
In the event that an advertiser is owed a credit as a result of adjustment of frequency rates, the publisher and advertising representative will provide credit only on future advertisements.
Payment Terms: Net 30 days of invoice date. Pre-payment discounts are available, contact publisher and advertising representative for more details.
Under-delivered Campaigns: Credits must be requested within 90-days of campaign conclusion.
Payment for New Advertisers: All new advertisers are required to prepay until credit and/or reference checks are completed. Once approved, Harborside payment terms are net 30 days. Contact the Harborside Finance Team at accounting@hbside.com for more details.
Viewability: 70% viewability is current industry standard. Ads taking more than 3 seconds to load will not qualify for viewability makegoods. Harborside utilizes a number of viewability/ivt analyzation tools for comprehensive data on advertising campaigns. If there is a 10% difference between third-party reporting, a conversation ensues between client and Harborside.
Advertiser may cancel the I/O as follows:
Cancellations in advertising by the advertiser or its agency may not be made after the closing date for the publication unless otherwise agreed to by both parties in writing.
Must be prior to 60 days of the published closing date. After the published closing date, any premium position, cover tip, or outsert is non-cancelable, and full payment is due.
Please see Print Advertising Rates for list of Premium Positions.
Same conditions apply for Best of JCO.
Editor-in-Chief
Jonathan W. Friedberg, MD, MMSc
JCO Editorial Office
E-mail: jco@asco.org
Phone: 703-797-1900
Fax: 703-684-8720
2318 Mill Road, Suite 800
Alexandria, VA 22314
Customer Service
E-mail: customerservice@asco.org
Phone: 888-282-2552 or 703-299-0158
2318 Mill Road, Suite 800
Alexandria, VA 22314
Hours: Monday–Friday,
8:30 AM–5:00 PM ET
To report an error, please send a message to: report.error@asco.org
Permissions
E-mail: jco@asco.orgpermissions@lww.com
Licensing
E-mail: HealthLicensing@wolterskluwer.com
VP Publishing at ASCO
Angela Cochran
Reprints
Reprints of journal articles may be purchased to support your commercial messaging.
For inquiries in the United States and Canada, please send your request to ReprintSolutions@wolterskluwer.com.
For inquiries regarding journal article reprint use in other countries,
please send your request to InternationalReprints@wolterskluwer.com.
For more information about reprints, visit the Reprints and Permissions page on the JCO website.
American Society of Clinical Oncology
2318 Mill Road, Suite 800, Alexandria, VA 22314
Tel: 571-483-1300 • www.asco.org
Associate Director
Miranda Walker
1-800-638-3030
miranda.walker@wolterskluwer.com
Chairman
John A. Gentile, Jr.
jgentile@hbside.com
President
Anthony Cutrone
acutrone@hbside.com
Executive Vice President
Conor Lynch
clynch@hbside.com
VP, Director of Advertising Sales
Leslie Dubin
631-935-7660
ldubin@hbside.com
VP, Senior Accounts Manager
Nick Vroom
917-538-0699
nvroom@hbside.com
Director of Business Development, Oncology
Sandy Haberman
W: 917-742-5583
shaberman@hbside.com
Production Manager
Norman W. Virtue
631-935-7682
nvirtue@hbside.com
SVP, Director of Sales
David Horowitz
631-935-7652
dhorowitz@hbside.com
Manager, Sales Support
Natalie King
631-572-4063
nking@hbside.com
Ad Sales Coordinators
adcoordinators@hbside.com
Ad Operations Group
digitalads@hbside.com